ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IWM icon
26
PUT
iShares Russell 2000 ETF
IWM
$76.4B
$18.8M 0.86%
62,500
+35,000
+127% +$9.84M
2025 Q4
2 quarters
SPY icon
27
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$813B
$18.7M 0.85%
+25,000
New +$18.1M
2026 Q2
0 quarters
NKTR icon
28
Nektar Therapeutics
NKTR
$1.26B
$17M 0.78%
244,184
+82,932
+51% +$6.07M
2024 Q3
7 quarters
INSP icon
29
Inspire Medical Systems
INSP
$1.97B
$16.7M 0.76%
374,617
-30,580
-8% -$1.45M
2025 Q3
3 quarters
RVMD icon
30
Revolution Medicines
RVMD
$41.5B
$16.4M 0.75%
87,509
-46,384
-35% -$6.78M
2024 Q3
7 quarters
ESTA icon
31
Establishment Labs
ESTA
$1.72B
$15.9M 0.73%
185,619
-27,854
-13% -$2M
2025 Q1
5 quarters
PRTA icon
32
Prothena Corp
PRTA
$430M
$15.2M 0.7%
1,554,535
-26,908
-2% -$266K
2025 Q2
4 quarters
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$5.97B
$15.1M 0.69%
136,158
-75,292
-36% -$6.81M
2024 Q4
6 quarters
IKT icon
34
Inhibikase Therapeutics
IKT
$251M
$15M 0.69%
7,387,205
+780,633
+12% +$1.4M
2024 Q4
6 quarters
QURE icon
35
uniQure
QURE
$1.45B
$15M 0.68%
324,672
+248,466
+326% +$6.5M
2025 Q3
3 quarters
RLYB icon
36
Rallybio
RLYB
$89.8M
$14.8M 0.68%
926,352
+905,817
+4,411% +$11.7M
2026 Q1
1 quarter
REGN icon
37
Regeneron Pharmaceuticals
REGN
$80.1B
$13.8M 0.63%
22,208
+10,054
+83% +$6.84M
2024 Q3
7 quarters
IVA icon
38
Inventiva
IVA
$678M
$13.6M 0.62%
3,606,656
+1,432,258
+66% +$6.88M
2025 Q4
2 quarters
STRO icon
39
Sutro Biopharma
STRO
$174M
$13.4M 0.61%
404,014
-120,427
-23% -$3.75M
2025 Q4
2 quarters
IONS icon
40
Ionis Pharmaceuticals
IONS
$7.1B
$13.2M 0.6%
166,286
+5,948
+4% +$448K
2025 Q2
4 quarters
BBIO icon
41
BridgeBio Pharma
BBIO
$12.7B
$13.2M 0.6%
176,689
+82,397
+87% +$5.77M
2023 Q4
10 quarters
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.78B
$13.1M 0.6%
730,649
+468,591
+179% +$8.86M
2023 Q4
10 quarters
CTMX icon
43
CytomX Therapeutics
CTMX
$486M
$12.6M 0.58%
3,365,118
-45,072
-1% -$172K
2024 Q1
9 quarters
VOR icon
44
Vor Biopharma
VOR
$1.11B
$12.5M 0.57%
+680,626
New +$10.3M
2026 Q2
0 quarters
BIL icon
45
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$50.8B
$12.4M 0.57%
135,585
– –
2023 Q4
10 quarters
EQ icon
46
Equillium
EQ
$82.4M
$12M 0.55%
3,758,569
+31,910
+0.9% +$76.5K
2025 Q3
3 quarters
ANL icon
47
Adlai Nortye Group ADS
ANL
$701M
$11.7M 0.54%
1,017,805
+899,896
+763% +$11M
2026 Q1
1 quarter
CLYM icon
48
Climb Bio
CLYM
$591M
$10.7M 0.49%
822,649
+224,987
+38% +$2.32M
2024 Q2
8 quarters
XBI icon
49
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$10.7M 0.49%
67,400
+52,400
+349% +$7.08M
2026 Q1
1 quarter
HLXC icon
50
Helix Acquisition Corp III
HLXC
$229M
$10.6M 0.49%
1,000,000
– –
2026 Q1
1 quarter
1
2
3 4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.